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PHA212 – Medicinal Chemistry 
DURATION 
 
Reading Time: 20 minutes 
Writing Time: 180 minutes 
 
INSTRUCTIONS TO CANDIDATES 
 
Section A:  
Suggested Time: 50 mins 
Short Answer Questions: Answer 3 from 4 questions 
Marks as indicated on paper. (Total marks = 30) 
Section B: 
Suggested time: 50 mins 
Short Answer Questions: Answer 3 from 4 questions 
Marks as indicated on paper. (Total marks = 30) 
Section C:  
Suggested time: 70 mins 
Short Answer Questions: Answer 2 from 3 questions 
Marks as indicated on paper. (Total marks = 40) 
EXAM CONDITIONS 
You may begin writing from the commencement of the examination session.  The reading time indicated above is 
provided as a guide only. 
This is a RESTRICTED OPEN BOOK examination 
Any non-programmable calculator is permitted 
One A4 sheet of handwritten double-sided notes permitted 
No dictionaries are permitted 
 
ADDITIONAL AUTHORISED MATERIALS EXAMINATION MATERIALS TO BE SUPPLIED 
 




1 x 20 Page Book 
1 x Scrap Paper 
Graph Paper 
Family Name  
Given Name/s  
Student Number       
Teaching Period Semester 1, 2019 
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Section A – The pharmaceutical industry & drug discovery 
Short Answer Questions 
Total No of Marks for this Section:  30 
 
Answer THREE questions in Section A 
This section should be answered in the Answer Booklet provided. 
 




Write 10 marks worth of material on a topic from the unit that is not covered in the other sections. 
Remember that the practicals are examinable material 
(Marks: 10) 
 
Question 2. Drug design process 
During the drug discovery, design and development process there are various checkpoints that can 
lead to project cancellation. 
 
As Chief Scientific Officer of a pharmaceutical company you have been asked to formulate the 
requirements for project progression. What information would you ask for your scientists to provide 
you with, in order to give them the go-ahead to progress a CNS active compound from the following 
development phases. Explain why you want each specific piece of information/results of experiments: 
i. Target selection 
ii. Candidate screening 
iii. Pre-clinical testing 
iv. Phase I clinical trials 
v. Phase III clinical trials 
(Marks: 10) 
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Question 3. Drug development for neglected tropical diseases  
Tropical diseases affect more than 1 billion people, mostly in developing regions of the world.  
(a) Give 2 examples of tropical diseases.  
(Marks: 2) 
(b) Give FOUR parameters for developing drugs targeting neglected tropical diseases (NTD) and 
compare/contrast the importance of those parameters in NTD drug development compared with 
development of drugs for diseases more common in developed countries. 
(Marks: 8) 
Question 4. ADME-T 
Fill in the blanks:  
 
(Marks: 4) 
Christopher Lipinski developed a series of ‘rules’ for drug development. What are these rules, and what 
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Section B – Drug-target interactions 
Short Answer Questions 
Total No of Marks for this Section:  30 
 
Answer THREE questions in Section B 
This section should be answered in the Answer Booklet provided. 
 
Marks for each question are indicated.  Suggested time allocation for Section B:  50 mins 
 
 
Question 5. Target binding 
(a) There are various ways that drugs modulate the action of receptors, channels and enzymes. 
Using diagrams explain the similarities and differences between the following: 
i. Competitive enzyme inhibition 
ii. Un-competitive inhibition 
iii. Allosteric modulation 
iv. Receptor agonism 
 
 (Marks: 8) 
(b) Rank the intermolecular forces in terms of strength. 
 (Marks: 2) 
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Question 6: QSAR/Log P 
Given the following data, design a compound that adheres to the Lipinski rules, that has a Log P value of 
4.03, with at least one hydrogen non-ring bond donor. You must use one of the core skeleton structures 
shown below. You are not allowed to expand the number of rings in the fused system.  
Explain your thinking 
 
 






1.02	 1.75	 0.82	 1.55	 1.68	
2.41	 2.22	 2.60	 2.52	
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Question 7: SAR/potency and selectivity 
 
You are a senior project scientist at a small 
biopharma company. Your project is to develop 
a compound based on oxytocin (OT) that will 
treat social deficits. Your team has synthesised a 
group of compounds (Table 1) and conducted 
activity and selectivity tests for the compounds 
(data in Table 2) agonising the human oxytocin 
receptor (hOTR) and the potential cross reactive 
receptor human vasopressin 1a receptor (hV1aR). 
Which compound(s) would you choose for 
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   You have been tasked with 
evaluating some screening-
optimisation data for a drug 
development project.  
Your drug scaffold is shown on the 
left. There are three potential variable locations, 
R2 attached to the ring system and R3/R4 at the 
amide  location. 
Using the structure-activity data in the tables, 
determine the best analogues that can be 
produced using the available structural 
elements. You should produce a ranking of five 
likely candidates and explain your reasoning in 
terms of potency (EC50) and selectivity (CC50). 
 
                                                                 (Marks: 10)
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Section C 
Short Answer Questions 
Total No of Marks for this Section:  40 
 
Answer Two questions in Section C 
This section should be answered on the exam paper and in the Answer Booklet provided as needed. 
 
Marks for each question are indicated.  Suggested time allocation for Section C:  70 mins 
 
 
Question 9. Medicinal chemistry of antibiotics (Figure A below) 
Discuss the medicinal chemistry of the following compounds in terms of their role in the anti-bacterial 
treatment, the mode and spectrum of their antibiotic action, their oral bioavailability, and their 
susceptibility to bacterial resistance mechanisms. 
 
Question 10 – Medicinal chemistry of chemotherapy (Figure B below) 
Compare and contrast the medicinal chemistry of the following anti-cancer agents. You should discuss 
their modes of action, how they preferentially attack cancer cells, and relate these to the structure and 
chemistry of each molecule. 
 
Question 11 – Medicinal chemistry of opiates (Figure C below) 
Study the morphine and opiate related compounds below. Discuss the medicinal chemistry of these 
compounds. Topics you may like to cover include: the pharmacophore of opiates, their relative potency, 
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